Evolution of incidental branch-duct intraductal papillary mucinous neoplasms of the pancreas: A study with magnetic resonance imaging cholangiopancreatography by Girometti, Rossano et al.
Rossano Girometti, Lorenzo Cereser, Chiara Zuiani, Institute 
of Diagnostic Radiology, Department of Medical and Biological 
Sciences, University of Udine, University Hospital “S. Maria 
della Misericordia”, p.le S. Maria della Misericordia, 15-33100 
Udine, Italy
Riccardo Pravisani, Sergio Giuseppe Intini, Andrea Risaliti, 
Clinical Surgery, Department of Medical and Biological 
Sciences, University of Udine, University Hospital “S. Maria 
della Misericordia”, p.le S. Maria della Misericordia, 15-33100 
Udine, Italy
Miriam Isola, Department of Medical and Biological Sciences, 
University of Udine, p.le Kolbe, 1-33100 Udine, Italy
Author contributions: Girometti R and Intini SG designed the 
study; Cereser L and Zuiani C reviewed imaging examinations; 
Pravisani R and Risaliti A reviewed clinical data; Girometti R, 
Pravisani R and Isola M collected all imaging and clinical data, 
organizing databases; Isola M performed statistical analysis; all 
the authors interpreted the results; Girometti R wrote the paper; 
all the authors reviewed the paper.
Institutional review board statement: The study was reviewed 
and approved by the Ethical Committee of the Friuli Venezia 
Giulia region, Italy.
Informed consent statement: By Italian regulations (Deter-
minazione Ministeriale 20. 03. 2008, Delibera del 15. 12. 2011 
del Garante per la Protezione dei Dati personali) informed consent 
acquisition is waived for retrospective studies involving analysis 
of anonymized data.
Conflict-of-interest statement: Nothing to disclose.
Data sharing statement: No additional data are available. 
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Invited manuscript
Correspondence to: Rossano Girometti, MD, Institute of 
Diagnostic Radiology, Department of Medical and Biological 
Sciences, University of Udine, University Hospital “S. Maria 
della Misericordia”, p.le S. Maria della Misericordia, via Colugna 
50, 15-33100 Udine, Italy. rgirometti@sirm.org
Telephone: +39-432-559266 
Fax: +39-432-559867
Received: July 19, 2016
Peer-review started: July 21, 2016
First decision: September 5, 2016
Revised: September 28, 2016
Accepted: October 27, 2016 
Article in press: October 27, 2016
Published online: November 21, 2016 
Abstract
AIM
To investigate the type and timing of evolution of 
incidentally found branch-duct intraductal papillary 
mucinous neoplasms (bd-IPMN) of the pancreas 
addressed to magnetic resonance imaging cholan-
giopancreatography (MRCP) follow-up.
METHODS
We retrospectively evaluated 72 patients who under-
went, over the period 2006-2016, a total of 318 MRCPs 
(mean 4.4) to follow-up incidental, presumed bd-
IPMN without signs of malignancy, found or confirmed 
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at a baseline MRCP examination. Median follow-up 
time was 48.5 mo (range 13-95 mo). MRCPs were 
acquired on 1.5T and/or 3.0T systems using 2D and/
or 3D technique. Image analysis assessed the rates 
of occurrence over the follow-up of the following 
outcomes: (1) imaging evolution, defined as any 
change in cysts number and/or size and/or appearance; 
and (2) alert findings, defined as worrisome features 
and/or high risk stigmata (e.g. , thick septa, parietal 
thickening, mural nodules and involvement of the main 
pancreatic duct). Time to outcomes was described 
with the Kaplan-Meir approach. Cox regression model 
was used to investigate clinical or initial MRCP findings 
predicting cysts changes.
RESULTS
We found a total of 343 cysts (per-patient mean 5.1) 
with average size of 8.5 mm (range 5-25 mm). Imaging 
evolution was observed in 32/72 patients (44.4%; 
95%CI: 32-9-56.6), involving 47/343 cysts (13.7%). 
There was a main trend towards small (< 10 mm) 
increase and/or decrease of cysts size at a median time 
of 22.5 mo. Alert findings developed in 6/72 patients 
(8.3%; 95%CI: 3.4-17.9) over a wide interval of time 
(13-63 mo). No malignancy was found on endoscopic 
ultrasound with fine-needle aspiration (5/6 cases) or 
surgery (1/6 cases). No clinical or initial MRCP features 
were significantly associated with changes in bd-IPMN 
appearance (P  > 0.01).
CONCLUSION
Changes in MRCP appearance of incidental bd-IPNM 
were frequent over the follow-up (44.4%), with 
relatively rare (8.3%) occurrence of non-malignant 
alert findings that prompted further diagnostic steps. 
Changes occurred at a wide interval of time and 
were unpredictable, suggesting that imaging follow-
up should be not discontinued, though MRCPs might 
be considerably delayed without a significant risk of 
missing malignancy. 
Key words: Pancreas; Cysts; Branch-duct intraductal 
papillary mucinous neoplasm; Magnetic resonance 
cholangiopancreatography; Follow-up
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Core tip: Branch-duct intraductal papillary mucinous 
neoplasms are a frequent incidental finding. The 
management of these lesions is challenging because of 
the need to balance low but concrete risk of developing 
malignancy over time versus costs of prolonged follow-
up procedures. In this retrospective study, we showed 
high rate of imaging evolution (44.4%), with 8.3% of 
patients developing alert findings prompting further 
diagnostic steps, though there were no final diagnoses 
of malignancy. Since there were no clinical or imaging 
predictors of alert findings, our results suggest that 
prolonged follow-up is useful, but might be significantly 
delayed with minimal risk of missing malignancy.
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INTRODUCTION
Branch-duct intraductal papillary mucinous neoplasm 
(bd-IPMN) is a subtype of pancreatic cystic tumor 
developing from mucin-producing columnar cells lining 
the side branches of the main pancreatic duct (MPD). 
Accumulation of mucin typically associates with cystic 
or saccular dilatation of the involved ducts[1]. Despite 
incidence of IPMN has been estimated rare (0.48-2.04 
per 100000 persons), most reports suggest that the 
frequency of disease increased over the last years, 
possibly because of the widespread use of sensitive 
imaging modalities such as computed tomography (CT) 
or Magnetic resonance imaging (MRI) with Magnetic 
resonance cholangiopancreatography (MRCP)[2]. Not 
surprisingly, most bd-IPMNs are discovered incidentally 
during examinations performed for causes unrelated 
to the pancreas[1,3,4]. Up to 70.6% of incidentally 
found pancreatic cysts show IPMN-like appearance on 
MRCP[5].
According to the Fukuoka consensus guidelines[1], 
bd-IPMN showing no symptoms, high-risk stigmata 
or worrisome morphological features can be follow-
up with serial imaging if cysts are ≤ 3 cm in size. 
Suggested follow-up methods [CT, MRI or endoscopic 
ultrasound (EUS)] as well as the timing of surveillance 
are driven by cysts size. However, the management 
of non-operated, presumed bd-IPMN is challenging 
because of the small but concrete potential of 
harboring high-grade dysplasia or malignancy (overall 
cancer risk as high as 2% per year)[3,6], regardless 
of the size[1,7]. Additionally, a growing body of data 
suggests an associated risk of developing concomitant 
pancreatic duct adenocarcinoma (about 4%)[3] or 
extrapancreatic cancer[2] in patients with bd-IPMN. 
Though a large amount of studies focused on 
the natural history of bd-IPMN[3,8], many of them 
did not clearly distinguish between symptomatic 
vs incidental lesion or suspicious vs not suspicious 
cysts at presentation, nor separated bd-IPMN from 
other cystic lesions of the pancreas. Moreover, 
little has been reported on the specific patterns of 
cysts evolution over time using MRCP, which is the 
examination of choice to evaluate bd-IPMN, given high 
contrast-resolution for fluid-containing structures[8]. 
This contributes to current uncertainty about the 
most appropriate scheduling and overall duration of 
imaging follow-up of incidental bd-IPMN, with impacts 
on costs, accessibility to examinations and patients’ 
quality of life. 
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The purpose of this study was to investigate MRCP 
patterns of evolution over time of incidental bd-IPMN 
showing no suspicious signs at the time of diagnosis. 
MATERIALS AND METHODS
Study population
This study was approved by local Ethical Committee 
and Hospital administration. Given the retrospective 
design, informed consent acquisition was waived, in 
accordance with laws and regulations of our country. 
We searched our institutional database (period 
June 2006-May 2016) to identify: (1) patients showing 
incidental pancreatic cysts on a baseline MRCP 
performed to evaluate conditions clinically unrelated 
to the pancreas; and (2) patients who underwent a 
baseline MRCP to assess pancreatic cysts incidentally 
found with previous ultrasonography (US) and/or CT 
performed no more than one month before. A total of 
153 subjects were found. 
Of them, we included: (1) those with at least one 
cyst ≥ 5 mm in largest size or more than two cysts of 
any size, with at least one cyst ≥ 5 mm showing clear 
communication with the MPD; and (2) patients with 
a minimum of two follow-up MRCPs covering a whole 
period of at least 24 mo, unless the study outcomes 
have been reached before (see below). We excluded 
from the study fifty subjects showing the following 
conditions: recent onset or worsening of diabetes 
mellitus, cysts with no definite communication with 
the MPD and/or showing MRCP appearance typical 
for other cysts type (e.g., mucinous cystic neoplasm), 
signs of chronic pancreatitis and, more importantly, 
patients showing incidental bd-IPMN- or mixed-IPMN-
like lesions with high risk stigmata and/or worrisome 
features (see below) at baseline examination (for 
which further diagnostic steps rather than imaging 
follow-up were required). We also excluded patients 
presenting with two or less cysts < 5 mm in size (n 
= 5), < 2 follow-up MRCPs (n = 17) and < 24 mo 
of follow-up period without cysts evolution (n = 9). 
Included patients showed a variety of indications to 
MRCP, mainly related to the biliary tract. None of them 
underwent MRI examinations prior to the baseline 
MRCP.
MRCP protocol
Baseline and follow-up examinations were performed 
on one of two 1.5T systems [Avanto (1) and Aera 
(2), Siemens Medical Systems, Erlangen, Germany] 
and/or a 3.0T magnet (Achieva, Philips HealthCare, 
Best, Netherlands) using a 8-channel, 18-channel and 
16-channel surface body coil, respectively. To minimize 
the overlap of fluid signal from the stomach and small 
bowel, we administered orally 1 mL of Gd-based 
contrast agent diluted into 9 mL of water (directly on 
the magnet, immediately before MRCP acquisition) or, 
prior to 2010, 250 mL of blueberry juice 20 min before 
patients started the examination. 
MRCP was performed with the 2D and/or 3D 
technique with the heavily T2-weighted sequences 
shown in Table 1. When using the 2D technique, eight 
single thick slices were placed along radial oblique 
coronal planes of the pancreas and biliary tree, at 
a distance of 20° each. In most cases, we acquired 
also 2D slices in the oblique transverse and oblique 
coronal planes of the pancreas. In the case of the 
3D sequence, one single slab was positioned on the 
oblique coronal plane to cover both the biliary tree 
and the pancreas, based on individual anatomy of 
the patient. In a few cases, one or more 2D slices or 
the 3D sequence were repeated to cover the whole 
pancreas if not initially included entirely. 
During baseline and follow-up examinations, MRCP 
was always associated, depending on the magnet, 
with the following sequences to provide anatomic 
representation of the upper abdomen and a reference 
for MRCP positioning: (1) transverse and coronal T2-
weighted Half-Fourier single-shot turbo spin echo 
(HASTE) or equivalent Single shot fast spin echo 
(SS-FSE); (2) transverse single-shot Echo-planar 
Diffusion-weighted imaging; and (3) transverse T1-
weighted 3D fat satured Volume Interpolatd Breath-
hold Examination (VIBE) or T1 High Resolution 
Isotropic Volume Exicitation (THRIVE) imaging. 
Optional sequences included transverse T1-weighted 
Gradient echo in-phase/out of-phase and transverse 
T2-weighted Short tau inversion recovery (STIR) 
or Spectrally adiabatic inversion recovery (SPAIR). 
Multiphasic contrast-enhanced study was performed in 
selected cases of extrapancreatic or pancreatic findings 
(e.g., larger cysts, suspicious findings, cysts evolution) 
using 0.1 mmol/kg of gadobenate dimeglumine 
(Multihance, Bracco, Milan, Italy) at an injection rate of 
2 mL/sec and a 3-4 mm thick transverse T1-weighted 
VIBE/THRIVE sequence. 
Image analysis
Image analysis was performed in consensus by 
a senior radiologist (13 years of experience in 
abdominal imaging) and a radiology resident (2 years 
of experience), who reviewed baseline and follow-
up examinations on two different workstations (Suite 
Estensa, Esaote, Genova, Italy; and Olea Sphere, Olea 
Medical, La Ciotat, France). 
By having access to MRCP and additional MRI 
sequences for problem-solving interpretation, ra-
diologists assessed the baseline pattern of cysts 
presentation, and then recorded any per-patient 
variation in terms of PC number (definite increase 
or decrease) and size (defined as any increase or 
decrease of at least 50% of the baseline largest 
diameter). They also assessed the occurrence during 
the follow-up of at least one of the following high-risk 
and/or worrisome findings as defined by Tanaka et 
al[1] in 2012: (1) cyst size ≥ 30 mm; (2) solid mural 
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findings occurrence over the total number of patients 
× 100. 
Time to radiological evolution or alert findings was 
described according to the Kaplan-Meier approach. Cox 
regression model was used to explore which clinical 
or imaging factor was associated with both outcomes. 
Variables included in the model were sex, age, type 
2 diabetes mellitus, previous cholecystectomy for 
stones, autoimmune systemic disorders, alcoholic 
liver cirrhosis, history of extrapancreatic neoplasia 
(solid cancer and/or hematologic malignancy), and the 
pattern of bd-IPMN presentation on baseline MRCP, 
that is cysts size (< 10 mm, 10-19 mm and ≥ 20 
mm) and cysts number (≤ 2, 2-5 and > 5).
Statistical analysis was performed by our referring 
biostatistician using a commercially available software 
(Stata/SE 14.1, Stata Corp LP, United States). Alfa 
level was sat 0.01.
RESULTS
bd-IPMN patterns on baseline MRCP 
Final study population included 72 subjects (17 male, 
55 female), with a mean age of 63.0 ± 9.4 years at 
the time of baseline MRCP (range 44-83 years). 
They showed a total of 343 PC arranged in a bd-
IPMN pattern, with a per-patient mean of 5.1 ± 2.4 
cysts (range 1-10). PC size spanned from 5 to 25 mm 
(mean size 8.5 ± 1.7 mm). Largest lesions’ diameter 
was lower than 10 mm in 277/343 cases (80.7%), 
between 10-19 mm in 58/343 (16.9%), and between 
20-29 mm in the remaining 8/343 cases (2.4%). 
None of the subjects developed symptoms related 
to the pancreas over the entire follow-up period.
Cysts variation over the follow-up
After baseline examination, patients underwent a total 
of 318 follow-up MRCPs, corresponding to a per-patient 
mean of 4.4 ± 2.0 examinations (range 2-12). Mean 
and median time of follow-up were 52.6 ± 22.4 and 
48.5 (range 13-95) mo, respectively, whereas mean 
and median interval of time between repeated MRCPs 
nodules with or without contrast enhancement; (3) 
wall thickening and/or thick/nodular internal septa; 
(4) dilatation of the MPD (caliber > 5 mm); and (5) 
abrupt change in the MPD caliber with distal pancreatic 
atrophy. Baseline size and subsequent variations 
were measured on HASTE/SS-FSE images and/or 2D 
MRCP images and/or thin source images in the case of 
the 3D MRCP using the same reference plane across 
different examinations. We followed the standards 
suggested by Dunn et al[9] to reduce variability in size 
measurement. When both techniques were available, 
3D MRCP was preferred to assess changes in size. In 
the case of multilocular cysts, lesion diameter was 
measured as a whole. Readers recorded the time of 
occurrence from baseline MRCP (in mo) of any of the 
above variations, as well as the number of follow-up 
MRCPs and the interval of time (in mo) between them.
Radiologists were blinded to medical history and 
patients’ workup data, which were independently 
reviewed and collected by a resident in surgery. In 
particular, he recorded any MRCP-induced EUS or 
surgery, as well as final diagnosis as established by 
EUS-guided fine-needle aspiration or histological 
examination after surgery.
Statistical analysis
Data on cyst number and distribution of cysts at the 
time of baseline MRCPs and during the follow-up are 
presented with descriptive statistic, reporting mean 
values (± SD) and/or median values (together with 
the range of minimum and maximum values). 
Concerning PC evolution, we assessed the preva-
lence of two outcomes over the whole period of follow-
up, namely: (1) imaging evolution, defined as any 
change in number and/or size and/or appearance 
occurred in ≥ 1 follow-up examination, involving ≥ 1 
cyst; (2) alert findings, defined as the occurrence of 
worrisome and/or high risk features prompting further 
investigation. According to our definitions, imaging 
evolution included cases of alert findings. Prevalence 
was calculated on a per-patient basis as the ratio 
between the cases of radiologic evolution or alert 
Table 1  Acquisition parameters of the magnetic resonance cholangiography sequences acquired in the study
1.5T (1) 1.5T (2) 3.0T
2D 3D 2D 3D 2D 3D
Sequence HASTE TSE HASTE TSE SS-FSE FSE
Type of acquisition Breath hold Navigator gated Breath hold Navigator gated Breath hold Respiratory 
triggered
TR (ms) 4000 2500 4500 2500 9449 1661.5
TE (ms)   735   685   725   700   740   401.2
FOV (mm × mm) 300 × 300 380 × 380 250 × 250 380 × 380 300 × 300 300 × 300
Matrix (pixel × pixel) 307 × 384 357 × 384 269 × 384 353 × 384 256 × 320 200 × 200
Number of slices 1 × 8 72 1 × 8 72 1 x 6 107
Slice thickness (mm) 40-50 1 50 1 40-50 0.75
Number of excitations 1 2 1 1.5 1 1
Acquisition time 4.5 s × 8 3 min 4 s (nominal) 4.5 s × 8 5 min 1 s (nominal) 9.3 s × 6 4 min 54 s 
(nominal)
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were 11.6 ± 6.7 and 17 (range 4-58) mo, respectively.
Over the entire follow-up, imaging evolution 
was observed in 32/72 patients (44.4%; 95%CI: 
32.9-56.6), involving 47/343 cysts (13.7; 95%CI: 
10.3-17.9) (per-patient mean 1.4 cysts). Table 2 
details evolution patterns and the timing of changes 
we observed. Overall, PC tended to increase and/or 
decrease in size rather than in number (Figure 1), with 
mean variation in size less than 10 mm (around 5 mm 
for the majority evolution patterns), except for two 10 
mm cysts in two patients which disappeared during the 
follow-up. In one patient (indicated as “other” in Table 
2), a total of six cysts less than 10 mm on baseline 
MRCP showed minimal change in size in repeated 
examinations, with the largest variation occurring in 
one cyst moving from 5 mm to 12 mm, followed by 
subsequent decrease in size to 7 mm. 
Alert findings developed in 6/72 patients (8.3%; 
95%CI: 3.4-17.9) as detailed in Table 3 (Figure 2). 
Except for one case, the occurrence of alert findings 
was preceded by other imaging evolution. 
Features predicting imaging evolution and/or alert 
findings
No clinical or baseline MRCP features were predictive 
of imaging evolution or alert findings development 
(P > 0.01) (Table 4). The only trend to statistical 
significance was observed for baseline cysts size > 10 
mm as a predictor of imaging evolution. 
The proportion of patients without imaging 
evolution estimated at 12, 24 and 60 mo was 86.1% 
(95%CI: 75.7-92.2), 73.5% (95%CI: 61.6-82.2) 
and 52.9% (95%CI: 37.2-66.4), respectively; 
the proportion of patients without alert findings 
estimated at 12, 24 and 60 mo was 100%, 97.2% 
(95%CI: 89.3-99.3) and 91.0% (95%CI: 79.2-96.2), 
respectively.
DISCUSSION
MRCP has been advocated as the procedure of 
choice for evaluating bd-IPMN, given the capability 
of assessing subtle findings such as smaller cysts, 
Table 2  Overall view of imaging evolution of incidental branch-duct intraductal papillary mucinous neoplasms cysts
Pattern of imaging evolution over the 
follow-up
Number of 
patients involved, 
n  (95%CI)
Total number of 
cysts involved/per-
patient mean 
number of cysts 
involved
Mean time of first 
change/mean time of 
last change1 (mo)
Median time of first 
change/median time of 
last change1 (mo), n  
(95%CI)
Mean size on baseline 
MRCP/Mean size at the 
end of the follow-up 
(mm)
Increase in size occurring in ≥ 1 
examination
14/72 17/1.2 34.2 ± 27.2/38.6 ± 29.6 23.5 (5-79)/25.5 (5-92) 8.4 ± 5.7/13.5 ± 6.9
19.4% (11.4-30.8)
Increase in size in ≥ 1 examination 
followed or alternating with a 
decrease in size and/or number in ≥ 1 
examination
5/72   8/1.6 21.0 ± 7.4/53.6 ± 23.0 21 (12-32)/48 (23-85) 8.4 ± 3.2/13.6 ± 6.1
6.9% (2.6-16.1)
Decrease in size occurring in ≥ 1 
examination
4/72   6/1.5 15.5 ± 16.8/17.7 ± 16.9 9 (4-40)/13.5 /(4-40) 14.7 ± 7.6/10.5 ± 9.1
5.6% (1.8-14.3)
Disappearance 2/72   2/1.0 20.0 ± 11.3/20.0 ± 11.3 20 (12-28)/20 (12-28) 10.0/0
1.4% (0.1-8.5)
Other2 1/72   6/6.0 5/89 5/89 5.0/7.0
1.4% (0.1-8.5)
Any type of evolution with 
development of alert findings
6/72   8/1.3 34.5 ± 19.9/42.1 ± 19.4 34 (15-63)/45.5 (13-71) 11.3 ± 6.4/15.8 ± 6.1
8.3% (3.4-17.9)
Total 32/72 47/1.4 28.1 ± 22.1/39.4 ± 26.9 22.5 (4-79)/32 (4-92)   9.7 ± 5.7/12.5 ± 7.3
44.4% (32.9-56.6)
1In the case of more than one change in cysts aspects during the follow-up; 2See the text for details. 
Figure 1  Small paraductal cysts in the pancreatic hystmus on baseline magnetic resonance cholangiopancreatography in a 65 years old female patient (A), 
showing increase in size at 24 mo (B) and then decrease in size at 36 mo (C).
A B C
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communication with the MPD, septa and mural 
nodules[10]. MRCP is accurate in diagnosing presumed 
bd-IPMN at initial presentation and in detecting 
changes occurring over the follow-up[3]. However, 
most studies in literature evaluated cysts evolution 
by alternating or replacing MRCP with other imaging 
modalities, including CT, EUS and endoscopic 
retrograde cholangiopancreatography[3,8,11,12]. This 
suggest that not all morphological changes over time 
might have been detected, thus limiting information on 
natural history. Not surprisingly, the per-patient rate 
of imaging evolution we observed was higher (44.4%) 
compared to most clinical studies (5.6%-28.0%)[13-18], 
though initial size of all cysts (average 8.5 ± 1.7 
mm) and the magnitude of changes in patients with 
evolution were comparably small (average size on 
baseline MRCP and at the end of the follow-up of 9.7 
mm vs 12.5 mm, respectively, with changes involving 
1.4 cysts per-patient). It should be pointed out that 
previous MRCP-based studies[19,20] found a lower 
imaging evolution rate (5%-10.8%) than ours in 
comparable patients populations. This discrepancy can 
be explained by our larger study population and/or by 
the fact we performed a cyst-by-cyst analysis rather 
Table 3  Overall view of alert findings occurrence in branch-duct intraductal papillary mucinous neoplasms cysts
Patient/sex/age 
on baseline 
MRCP
Type and timing of alert 
finding occurrence
Type and timing of 
associated imaging 
evolution
Final diagnosis Standard of reference Notes
1/female/58 yr Non-enhancing small 
filling defect at 48 mo in an 
8 mm cyst, increased from 
previous control
The same cyst showed 
initial increase in size 
(from 5 mm to 8 mm) at 12 
mo, followed by decrease 
(from 8 mm to 5 mm) at 
18 mo
Mucin plug; no dysplasia 
or invasive cancer
EUS with FNA: mucin 
plug, negative cytology
-
2/male/59 yr Thickened/nodular septa 
at 15 mo
Minimal increase of two 
cysts at 6 mo
No dysplasia or invasive 
cancer
EUS: negative 
examination
No further evolution 
over the whole follow-up 
(24 mo). Patient died for 
alcoholic liver cirrhosis
3/female/68 yr Non-enhancing filling 
defect at 43 mo
Disappearance of a 9 mm 
cyst at 33 mo
Mucin plug; no dysplasia 
or invasive cancer
EUS with FNA: negative 
cytology
-
4/female/55 yr Thickened/nodular septa 
at 63 and then 71 mo
Increase in size of the 
same cyst from 10 mm to 
15 mm at 9 mo
Low-grade dysplasia bd-
IPMN
EUS with FNA: low grade 
dysplasia bd-IPMN, 
negative CEA and CA 19.9
Non further evolution 
over the whole follow-up 
(99 mo)
5/female/60 yr Dilation of the main 
pancreatic duct (head, 
caliber 9 mm) and mural 
filling defects in the larger 
cyst (15 mm) at 25 mo
No other evolution 
observed
Evolution from bd-IPMN 
to mixed-type IPMN
EUS with FNA (repeated 
3 times): negative 
cytology, elevated CEA, 
CA 19.9 and amylase. No 
vascularization of filling 
defects on Color Doppler 
exam
Liver-transplanted patient 
(alcoholic cirrhosis) in 
whom pancreatic surgery 
was unfeasible. No further 
evolution over the whole 
follow up period (92 mo)
6/female/72 yr Increase in size of one cyst 
from 20 mm to 30 mm at 
13 mo
Increase in size of the 
same cyst from 16 mm to 
20 mm at 9 mo
No dysplasia or invasive 
cancer
Histological examination 
after surgical resection of 
the cyst
Occurrence of the alert 
finding preceded by 
negative EUS
No further evolution over 
the subsequent follow-up 
(39 mo)
bd-IPMN: Branch-duct intraductal papillary mucinous neoplasms.
Table 4  Results of the Cox proportional hazard analysis
Clinical or imaging feature Imaging evolution Alert findings
HR P value 95%CI HR P value 95%CI
Sex 0.78 0.569 0.33-1.81 0.60 0.644 0.69-5.19
Age 0.98 0.488 0.95-1.02 1.00 0.967 0.92-1.08
Previous cholecistectomy 0.89 0.794 0.40-2.00 -1
Diabetes mellitus (type 2) 0.92 0.873 0.34-2.44 2.39 0.316   0.43-13.14
Autoimmune systemic disease 0.58 0.218 0.25-1.36 0.51 0.543 0.59-4.39
Alcoholic liver cirrhosis 1.88 0.143 0.80-4.40 2.49 0.295   0.45-13.75
History of extrapancreatic neoplasia 1.79 0.109 0.87-3.68 0.70 0.694 0.12-3.93
Cysts size > 10 mm on baseline MRCP 2.13 0.055 0.98-4.64 4.02 0.205   0.46-34.70
Number of cysts on baseline MRCP 1.42 0.590 0.70-1.96 1.26 0.680 0.40-3.95
1No patients showing the outcome. MRCP: Magnetic resonance cholangiopancreatography. 
Girometti R et al . Evolution of bd-IPMN on MRCP
9568 November 21, 2016|Volume 22|Issue 43|WJG|www.wjgnet.com
than focusing on target ones, as supported by similar 
evolution rate (48.5% increase in size, 1.5% decrease 
in size) in a clinical study by Bae et al[11] with same 
type of analysis.
Imaging evolution included development of alert 
findings in 8.3% of patients, a value within the range 
of those previously reported in studies with MRCP 
(2.7%-10.8%)[19-22] or combined imaging modalities 
(4.9%-9%)[14,17]. None of them corresponded to 
“high-risk stigmata” according to Sendai guidelines 
definition, but rather to worrisome features[1]. Except 
for one patient who developed mixed-type IPMN, 
small changes preceded alert findings at a variable, 
unpredictable extent of time, involving both evolved 
cysts or not. Four out of 6 patients with alert findings 
showed no abnormalities on EUS with FNA (3 cases) 
and histological examination after surgery (1 case). 
Remaining EUS-based diagnoses were low-dysplasia in 
one patient refusing surgery and evolution to mixed-
type IPMN in a liver-transplanted patient in whom 
surgery was unfeasible because of poor health status. 
Both showed lesion stability during the follow-up (92 
and 99 mo, respectively). Similarly to previous MRCP-
based studies on smaller populations[19,20], we observed 
no evolution to overt malignancy.
Our results suggest that small changes in the 
appearance of incidental bd-IPMN are common when 
the follow-up is performed with MRCP, likely reflecting 
a dynamic process of filling/empting of cystic mucin 
content and/or plug formation. In many cases, changes 
occurred repeatedly in different MRCP examinations, 
with a trend to progressive, small and slow progression 
that is in line with previous observations[21]. In 
particular, the median time of first and last occurrence 
was 22.5 and 32 mo, respectively, with about one-
half of patients having manifested evolution at 60 mo, 
suggesting that imaging evolution can occur whenever 
during the follow-up. Furthermore, no clinical factors or 
cysts appearance on baseline MRCP were predictors of 
imaging evolution, with the partial, but not significant (P 
= 0.055) exception of size > 10 mm. 
One can hypothesize some clinical consequences 
for the management of incidental, presumed bd-
IPMN. First, imaging evolution on MRCP should not 
prompt interventions, additional diagnostic steps or 
change in scheduled follow-up unless alert findings 
occur. Second, since there was no definite proof 
for malignancy in most patients who develop alert 
findings, careful risk-to-benefit evaluation should be 
made before addressing them to invasive and costing 
diagnosis or treatment. In the case of subtle and 
ambiguous findings, interventions might be deferred, 
using MRCP to follow-up patients at a shorter time (e.g., 
every six mo from the alert findings for the first year) 
unless further evolution or stability are demonstrated. 
Crippa et al[23] have recently shown that conservative 
management in patients developing worrisome 
features is appropriate, with 5-year disease-survival of 
96%. Our results showed that alert findings occurrence 
was quite variable in time (range 13-63 mo). More 
importantly, alert findings were unpredictable based on 
cysts pattern or clinical features. Given the low rate of 
occurrence (91% of alert findings-free patients at 60 
mo) and risk they really correspond to malignancy (or 
rapidly evolving malignancy), one might hypothesize 
that follow-up should continue over time, possibly 
with longer intervals between examinations to avoid 
“oversuveillance”, e.g., every 2 years as previously 
suggested[24]. 
Our study shows some limitations. First, there 
was no histological confirmation of bd-IPMN in our 
series, as well as the majority of alert findings (5/6), 
though EUS with FNA was performed in those cases. 
However, our results reflects clinical practice, in which: 
(1) MRCP is considered the most reliable noninvasive 
tool to diagnose and follow-up presumed bd-IPMN[3]; 
and (2) final diagnosis cannot be frequently obtained 
in patients with alert findings because of age and 
comorbidities contraindicating surgery, mirroring the 
“incidental” setting. It would be unfeasible/unethical to 
address patients to unnecessary invasive procedures. 
On the other hand, none of the alert findings showed 
evolution to overt malignancy during the follow-up. 
Second, number and timing of follow-up examina-
Figure 2  Occurrence of alert findings in patient number 5 described in Table 3. Compared to the baseline examination (A), follow-up MRCP (B) showed main 
pancreatic duct dilation and small parietal filling defects in the body cyst. MRCP: Magnetic resonance cholangiopancreatography. 
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tions were inhomogeneous, given the retrospective 
design. Further studies with a prospective and more 
homogeneous follow-up scheduling may support our 
findings.
In conclusion, incidentally found cysts arranged in 
a bd-IPMN pattern showed 44.4% evolution rate when 
monitored with MRCP, mainly in terms of minimal 
increase in size. The rate of occurrence of alert 
findings prompting further diagnostic step was 8.3%, 
with no definite proof of malignancy nor significant 
impact on patients’ management. Time to evolution 
and/or alert findings was quite variable, whereas 
no clinical or baseline MRCP findings were found to 
predict both types of changes. Our results suggest 
that imaging follow-up of incidental bd-IPMN should 
not be discontinued, though examinations might be 
considerably delayed with a minimal risk of missing 
malignancy. Further studies should clarify whether 
rescheduling the interval of time between follow-up 
examinations is an effective strategy in managing 
patients who develop alert findings.
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